Merck & Company's edible treatment 'Laguebrio Capsule' will be prescribed to Corona 19 patients from today (26th).
According to the Korea Centers for Disease Control and Prevention (KCDC), the first 20,000 pieces of La Gabrio, introduced on the 24th, will be supplied to medical sites such as infectious disease hospitals from today.
The target of administration is patients over 60 years of age who have been showing symptoms of COVID-19 within 5 days, patients over 40 years of age with underlying diseases, and patients who have difficulty using existing treatments among immunocompromised patients.
Pregnant women and children and adolescents under the age of 18 are excluded from the treatment.
Authorities plan to introduce 100,000 Lagevrios by the end of this month, in addition to the 80,000 servings that will be additionally introduced in Korea on the 27th.